Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | SQLE | Q14534 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9159020 | 1.00 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL9159032 | 1.00 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL24092723 | 1.00 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL228928 | 0.95 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL1771234 | 0.95 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL228929 | 0.95 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL9137864 | 0.95 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL9138262 | 0.95 | KMT2A (0.77) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL9157286 | 0.93 | KMT2A (0.64) | KMT2ASQLEMAPTALDH1A1MEN1 | |
| SCHEMBL9157291 | 0.93 | KMT2A (0.64) | KMT2ASQLEMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-12-22 | — | — | US | disclosed |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-25 | — | — | US | disclosed |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-22 | — | — | US | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| EP-3523437-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2019-08-14 | — | — | EP | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
| EP-3463386-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2019-04-10 | — | — | EP | disclosed |
| US-20190008986-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-01-10 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KMT2A 1986/4885SQLE 4262/4885MAPT 1951/4885 |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | KMT2A 2880/4885SQLE 1743/4885MAPT 4884/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | KMT2A 1618/4885SQLE 2239/4885MAPT 4749/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | KMT2A 4217/4885SQLE 274/4885MAPT 3184/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KMT2A 1986/4885SQLE 4262/4885MAPT 1951/4885 |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | KMT2A 1618/4885SQLE 2239/4885MAPT 4749/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | KMT2A 1618/4885SQLE 2239/4885MAPT 4749/4885 |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | KMT2A 1618/4885SQLE 2239/4885MAPT 4749/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | KMT2A 3504/4885SQLE 4793/4885MAPT 2391/4885 |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | KMT2A 4006/4885SQLE 290/4885MAPT 2954/4885 |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | KMT2A 1986/4885SQLE 4262/4885MAPT 1951/4885 |
| US-20190008986-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KMT2A 1986/4885SQLE 4262/4885MAPT 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.